Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2715-2721

  Shen, Dong ^a,b   Guo, Cheng Cheng ^a   Wang, Jing ^a   Qiu, Zhi Kun ^a   Sai, Ke ^a   Yang, Qun Ying ^a   Chen, Yin Sheng ^a   Chen, Fu Rong ^a   Wang, Jie ^a   Panasci, Lawrence ^c   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b JIANGYIN PEOPLE S HOSPITAL   (China)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Glioma stem like cells; Interferon ; MGMT; NF B; Temozolomide

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; INTERFERON; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME REGULATION; GLIOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTERFERON TYPE I; MALE; MICE; NEOPLASTIC STEM CELLS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941900385     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4232     Document Type: Article

References (32)

1. CBTRUS: CBTRUS Statistical report: Primary brain and central nervoussystem tumors diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States CBTRUS; Hindsdale, IL, USA, 2011. www.cbtrus.org.
2. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
4. Fukushima T, Takeshima H and Kataoka H: Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 29: 4845-4854, 2009.
5. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV and Kovacs K: Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29: 3759-3768, 2009.
6. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W and Parker R: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12: 4523-4532, 2006.
7. Hermisson M, Klumpp A, Wick W, et al: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776, 2006.
8. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
9. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
10. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206, 2002.
11. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
12. K ondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
13. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241, 2006.
14. Salmaggi A, Boiardi A, Gelati M, et al: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54: 850-860, 2006.
15. Jonasch E and Haluska FG: Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55, 2001.
16. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M and Yoshida J: A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: Novel findings from gene expression profiling and autopsy. J Gene Med 10: 329-339, 2008.
17. Groves MD, Puduvalli VK, Gilbert MR, et al: Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101: 615-620, 2009.
18. Ohno M, Natsume A, Fujii M, Ito M and Wakabayashi T: Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer 53: 37-41, 2009.
19. Warren K, Bent R, Wolters PL, et al: A phase 2 study of pegylated interferon α-2b (PEG-Intron®) in children with diffuse intrinsic pontine glioma. Cancer 118: 3607-3613, 2012.
20. Natsume A, Ishii D, Wakabayashi T, et al: IFN-beta downregulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579, 2005.
21. Natsume A, Wakabayashi T, Ishii D, et al: A combination of IFN-beta and temozolomide in human glioma xenograft models: Implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61: 653-659, 2008.
22. Lavon I, Fuchs D, Zrihan D, et al: Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O6-methylguanine-DNA-methyltransferase. Cancer Res 67: 8952-8959, 2007.
23. Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
24. Qiu ZK, Shen D, Chen YS, et al: Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer 33: 115-122, 2014.
25. Tubbs JL, Pegg AE and Tainer JA: DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair 6: 1100-1115, 2007.
26. Chen ZP, Yarosh D, Garcia Y, et al: Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 26: 104-109, 1999.
27. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
28. Hegi ME, Liu L, Herman JG, et al: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008.
29. Colman H1, Berkey BA, Maor MH, et al; Radiation Therapy Oncology Group: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: Results of RTOG 9710. Int J Radiat Oncol Biol Phys 66: 818-824, 2006.
30. Motomura K, Natsume A, Kishida Y, et al: Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730, 2011.
31. Saccani S, Marazzi I, Beg AA and Natoli G: Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 200: 107-113, 2004.
32. Sethi G, Ahn KS, Sung B and Aggarwal BB: Pinitol targets nuclear factor-kappaB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther 7: 1604-1614, 2008.